Defense Health Program Department of Defense Kidney Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
The FY21 Defense Appropriations Act provides funding to the Department of Defense Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY21 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
Applications submitted to the FY21 KCRP must address one or more of the following focus areas:
- Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
- Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
- Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
- Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations and drug delivery systems.
- Identify and implement strategies to improve the quality of life of patients.
- Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
https://cdmrp.army.mil/funding/kcrp
Concept Award – Letter of Intent due June 22, 2021
All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible. • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. • Emphasis on innovation. • Preliminary data are not allowed. • Clinical trials are not allowed. • Blinded review. • Maximum of $75,000 for direct costs (plus indirect costs). • Maximum period of performance is 1 year. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
|
Idea Development Award – Preproposal due June 15, 2021
Modified for FY21
Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
Early-Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission.
• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Innovation and Impact are the most important review criteria.
• Different funding options, based on the scope of the proposed research, are available with compelling justification.
• Preliminary data are required.
• Clinical trials are not allowed.
Maximum funding of $600,000 in direct costs (plus indirect costs).
• Period of performance not to exceed 3 years.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
Early Detection Studies Option:
• Maximum funding of $650,000 in direct costs (plus indirect costs).
• Period of performance not to exceed 3 years.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
Population Science and Prevention Studies Option:
• Maximum funding of $2 million in direct costs (plus indirect costs).
• Period of performance not to exceed 4 years.
Postdoctoral and Clinical Fellowship Award – Letter of Intent due June 22, 2021
• Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers. • A designated mentor who is an experienced kidney cancer researcher is required. • Clinical trials are not allowed. • Maximum funding of $195,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
|
Translational Research Partnership Award
The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent.
The Partnering PI must be at or above the level of Assistant Professor or equivalent.
Postdoctoral fellows are not eligible to be Partnering PIs.
• Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
• Supports translational correlative studies.
• Preliminary data are required.
• Clinical trials are not allowed.
• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507